Gut microbiota mediated molecular events and therapy in liver diseases
Gut microbiota is a community of microorganisms that reside in the gastrointestinal tract. An increasing number of studies has demonstrated that the gut-liver axis plays a critical role in liver homeostasis. Dysbiosis of gut microbiota can cause liver diseases, including nonalcoholic fatty liver dis...
Gespeichert in:
| Veröffentlicht in: | World journal of gastroenterology : WJG 2020-12, Vol.26 (48), p.7603-7618 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 7618 |
|---|---|
| container_issue | 48 |
| container_start_page | 7603 |
| container_title | World journal of gastroenterology : WJG |
| container_volume | 26 |
| creator | Qi, Xiaoqiang Yang, Ming Stenberg, Joseph Dey, Rahul Fogwe, Leslie Alam, Muhammad Shawkat Kimchi, Eric T Staveley-O'Carroll, Kevin F Li, Guangfu |
| description | Gut microbiota is a community of microorganisms that reside in the gastrointestinal tract. An increasing number of studies has demonstrated that the gut-liver axis plays a critical role in liver homeostasis. Dysbiosis of gut microbiota can cause liver diseases, including nonalcoholic fatty liver disease and alcoholic liver disease. Preclinical and clinical investigations have substantiated that the metabolites and other molecules derived from gut microbiota and diet interaction function as mediators to cause liver fibrosis, cirrhosis, and final cancer. This effect has been demonstrated to be associated with dysregulation of intrahepatic immunity and liver metabolism. Targeting these findings have led to the development of novel preventive and therapeutic strategies. Here, we review the cellular and molecular mechanisms underlying gut microbiota-mediated impact on liver disease. We also summarize the advancement of gut microbiota-based therapeutic strategies in the control of liver diseases. |
| doi_str_mv | 10.3748/wjg.v26.i48.7603 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7789060</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2482670683</sourcerecordid><originalsourceid>FETCH-LOGICAL-c462t-ae52b4313dce38ca276219683971817c9434ced342d7b03c58aba9eaa35c55523</originalsourceid><addsrcrecordid>eNpVkD1PwzAQhi0EoqWwMyGPLCmOP2JnQUKIAlIlFpiti3OAq3wUOwni32NUQDC9w7139-gh5DRnS6GluXjfvCwnXiy9NEtdMLFH5pznZcaNZPtknjOms1JwPSNHMW4Y40IofkhmKZjKRTknq9txoK13oa98PwBtsfYwYE3bvkE3NhAoTtgNkUJX0-EVA2w_qO9o4ycMtPYRIWI8JgfP0EQ8-c4FeVrdPF7fZeuH2_vrq3XmZMGHDFDxSopc1A6FccB1kXALI0qdm1y7UgrpsBaS17piwikDFZQIIJRTSnGxIJe7u9uxSqgukQVo7Db4FsKH7cHb_5POv9qXfrJam5IlQwty_n0g9G8jxsG2PjpsGuiwH6Pl0vBCs4SUqmxXTXJiDPj8-yZn9ku_Tfpt0m-TfvulP62c_cX7XfjxLT4B5hmDKw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2482670683</pqid></control><display><type>article</type><title>Gut microbiota mediated molecular events and therapy in liver diseases</title><source>MEDLINE</source><source>Baishideng "World Journal of" online journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Qi, Xiaoqiang ; Yang, Ming ; Stenberg, Joseph ; Dey, Rahul ; Fogwe, Leslie ; Alam, Muhammad Shawkat ; Kimchi, Eric T ; Staveley-O'Carroll, Kevin F ; Li, Guangfu</creator><creatorcontrib>Qi, Xiaoqiang ; Yang, Ming ; Stenberg, Joseph ; Dey, Rahul ; Fogwe, Leslie ; Alam, Muhammad Shawkat ; Kimchi, Eric T ; Staveley-O'Carroll, Kevin F ; Li, Guangfu</creatorcontrib><description>Gut microbiota is a community of microorganisms that reside in the gastrointestinal tract. An increasing number of studies has demonstrated that the gut-liver axis plays a critical role in liver homeostasis. Dysbiosis of gut microbiota can cause liver diseases, including nonalcoholic fatty liver disease and alcoholic liver disease. Preclinical and clinical investigations have substantiated that the metabolites and other molecules derived from gut microbiota and diet interaction function as mediators to cause liver fibrosis, cirrhosis, and final cancer. This effect has been demonstrated to be associated with dysregulation of intrahepatic immunity and liver metabolism. Targeting these findings have led to the development of novel preventive and therapeutic strategies. Here, we review the cellular and molecular mechanisms underlying gut microbiota-mediated impact on liver disease. We also summarize the advancement of gut microbiota-based therapeutic strategies in the control of liver diseases.</description><identifier>ISSN: 1007-9327</identifier><identifier>EISSN: 2219-2840</identifier><identifier>DOI: 10.3748/wjg.v26.i48.7603</identifier><identifier>PMID: 33505139</identifier><language>eng</language><publisher>United States: Baishideng Publishing Group Inc</publisher><subject>Dysbiosis ; Gastrointestinal Microbiome ; Humans ; Liver ; Minireviews ; Non-alcoholic Fatty Liver Disease - therapy ; Probiotics - therapeutic use</subject><ispartof>World journal of gastroenterology : WJG, 2020-12, Vol.26 (48), p.7603-7618</ispartof><rights>The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.</rights><rights>The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. 2020</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c462t-ae52b4313dce38ca276219683971817c9434ced342d7b03c58aba9eaa35c55523</citedby><cites>FETCH-LOGICAL-c462t-ae52b4313dce38ca276219683971817c9434ced342d7b03c58aba9eaa35c55523</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789060/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789060/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33505139$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Qi, Xiaoqiang</creatorcontrib><creatorcontrib>Yang, Ming</creatorcontrib><creatorcontrib>Stenberg, Joseph</creatorcontrib><creatorcontrib>Dey, Rahul</creatorcontrib><creatorcontrib>Fogwe, Leslie</creatorcontrib><creatorcontrib>Alam, Muhammad Shawkat</creatorcontrib><creatorcontrib>Kimchi, Eric T</creatorcontrib><creatorcontrib>Staveley-O'Carroll, Kevin F</creatorcontrib><creatorcontrib>Li, Guangfu</creatorcontrib><title>Gut microbiota mediated molecular events and therapy in liver diseases</title><title>World journal of gastroenterology : WJG</title><addtitle>World J Gastroenterol</addtitle><description>Gut microbiota is a community of microorganisms that reside in the gastrointestinal tract. An increasing number of studies has demonstrated that the gut-liver axis plays a critical role in liver homeostasis. Dysbiosis of gut microbiota can cause liver diseases, including nonalcoholic fatty liver disease and alcoholic liver disease. Preclinical and clinical investigations have substantiated that the metabolites and other molecules derived from gut microbiota and diet interaction function as mediators to cause liver fibrosis, cirrhosis, and final cancer. This effect has been demonstrated to be associated with dysregulation of intrahepatic immunity and liver metabolism. Targeting these findings have led to the development of novel preventive and therapeutic strategies. Here, we review the cellular and molecular mechanisms underlying gut microbiota-mediated impact on liver disease. We also summarize the advancement of gut microbiota-based therapeutic strategies in the control of liver diseases.</description><subject>Dysbiosis</subject><subject>Gastrointestinal Microbiome</subject><subject>Humans</subject><subject>Liver</subject><subject>Minireviews</subject><subject>Non-alcoholic Fatty Liver Disease - therapy</subject><subject>Probiotics - therapeutic use</subject><issn>1007-9327</issn><issn>2219-2840</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkD1PwzAQhi0EoqWwMyGPLCmOP2JnQUKIAlIlFpiti3OAq3wUOwni32NUQDC9w7139-gh5DRnS6GluXjfvCwnXiy9NEtdMLFH5pznZcaNZPtknjOms1JwPSNHMW4Y40IofkhmKZjKRTknq9txoK13oa98PwBtsfYwYE3bvkE3NhAoTtgNkUJX0-EVA2w_qO9o4ycMtPYRIWI8JgfP0EQ8-c4FeVrdPF7fZeuH2_vrq3XmZMGHDFDxSopc1A6FccB1kXALI0qdm1y7UgrpsBaS17piwikDFZQIIJRTSnGxIJe7u9uxSqgukQVo7Db4FsKH7cHb_5POv9qXfrJam5IlQwty_n0g9G8jxsG2PjpsGuiwH6Pl0vBCs4SUqmxXTXJiDPj8-yZn9ku_Tfpt0m-TfvulP62c_cX7XfjxLT4B5hmDKw</recordid><startdate>20201228</startdate><enddate>20201228</enddate><creator>Qi, Xiaoqiang</creator><creator>Yang, Ming</creator><creator>Stenberg, Joseph</creator><creator>Dey, Rahul</creator><creator>Fogwe, Leslie</creator><creator>Alam, Muhammad Shawkat</creator><creator>Kimchi, Eric T</creator><creator>Staveley-O'Carroll, Kevin F</creator><creator>Li, Guangfu</creator><general>Baishideng Publishing Group Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20201228</creationdate><title>Gut microbiota mediated molecular events and therapy in liver diseases</title><author>Qi, Xiaoqiang ; Yang, Ming ; Stenberg, Joseph ; Dey, Rahul ; Fogwe, Leslie ; Alam, Muhammad Shawkat ; Kimchi, Eric T ; Staveley-O'Carroll, Kevin F ; Li, Guangfu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c462t-ae52b4313dce38ca276219683971817c9434ced342d7b03c58aba9eaa35c55523</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Dysbiosis</topic><topic>Gastrointestinal Microbiome</topic><topic>Humans</topic><topic>Liver</topic><topic>Minireviews</topic><topic>Non-alcoholic Fatty Liver Disease - therapy</topic><topic>Probiotics - therapeutic use</topic><toplevel>online_resources</toplevel><creatorcontrib>Qi, Xiaoqiang</creatorcontrib><creatorcontrib>Yang, Ming</creatorcontrib><creatorcontrib>Stenberg, Joseph</creatorcontrib><creatorcontrib>Dey, Rahul</creatorcontrib><creatorcontrib>Fogwe, Leslie</creatorcontrib><creatorcontrib>Alam, Muhammad Shawkat</creatorcontrib><creatorcontrib>Kimchi, Eric T</creatorcontrib><creatorcontrib>Staveley-O'Carroll, Kevin F</creatorcontrib><creatorcontrib>Li, Guangfu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>World journal of gastroenterology : WJG</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Qi, Xiaoqiang</au><au>Yang, Ming</au><au>Stenberg, Joseph</au><au>Dey, Rahul</au><au>Fogwe, Leslie</au><au>Alam, Muhammad Shawkat</au><au>Kimchi, Eric T</au><au>Staveley-O'Carroll, Kevin F</au><au>Li, Guangfu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gut microbiota mediated molecular events and therapy in liver diseases</atitle><jtitle>World journal of gastroenterology : WJG</jtitle><addtitle>World J Gastroenterol</addtitle><date>2020-12-28</date><risdate>2020</risdate><volume>26</volume><issue>48</issue><spage>7603</spage><epage>7618</epage><pages>7603-7618</pages><issn>1007-9327</issn><eissn>2219-2840</eissn><abstract>Gut microbiota is a community of microorganisms that reside in the gastrointestinal tract. An increasing number of studies has demonstrated that the gut-liver axis plays a critical role in liver homeostasis. Dysbiosis of gut microbiota can cause liver diseases, including nonalcoholic fatty liver disease and alcoholic liver disease. Preclinical and clinical investigations have substantiated that the metabolites and other molecules derived from gut microbiota and diet interaction function as mediators to cause liver fibrosis, cirrhosis, and final cancer. This effect has been demonstrated to be associated with dysregulation of intrahepatic immunity and liver metabolism. Targeting these findings have led to the development of novel preventive and therapeutic strategies. Here, we review the cellular and molecular mechanisms underlying gut microbiota-mediated impact on liver disease. We also summarize the advancement of gut microbiota-based therapeutic strategies in the control of liver diseases.</abstract><cop>United States</cop><pub>Baishideng Publishing Group Inc</pub><pmid>33505139</pmid><doi>10.3748/wjg.v26.i48.7603</doi><tpages>16</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1007-9327 |
| ispartof | World journal of gastroenterology : WJG, 2020-12, Vol.26 (48), p.7603-7618 |
| issn | 1007-9327 2219-2840 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7789060 |
| source | MEDLINE; Baishideng "World Journal of" online journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Dysbiosis Gastrointestinal Microbiome Humans Liver Minireviews Non-alcoholic Fatty Liver Disease - therapy Probiotics - therapeutic use |
| title | Gut microbiota mediated molecular events and therapy in liver diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T08%3A02%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gut%20microbiota%20mediated%20molecular%20events%20and%20therapy%20in%20liver%20diseases&rft.jtitle=World%20journal%20of%20gastroenterology%20:%20WJG&rft.au=Qi,%20Xiaoqiang&rft.date=2020-12-28&rft.volume=26&rft.issue=48&rft.spage=7603&rft.epage=7618&rft.pages=7603-7618&rft.issn=1007-9327&rft.eissn=2219-2840&rft_id=info:doi/10.3748/wjg.v26.i48.7603&rft_dat=%3Cproquest_pubme%3E2482670683%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2482670683&rft_id=info:pmid/33505139&rfr_iscdi=true |